It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

pharmaceuticals

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
Shionogi says its COVID-19 shot is effective and safe

National Mar 6, 2022

Shionogi says its COVID-19 shot is effective and safe

by Kanoko Matsuyama and Grace Huang

The positive data could mean Japan, which is racing to complete a booster drive in hopes of curbing future outbreaks, will soon have an indigenous jab.

Japan’s petrochemical firms need to merge to survive, Mitsubishi Chemical CEO says

Business / Corporate Feb 25, 2022

Japan’s petrochemical firms need to merge to survive, Mitsubishi Chemical CEO says

by Shoko Oda and Gearoid Reidy

Jean-Marc Gilson compared the situation facing the chemical industry to other industries Japan once dominated, such as semiconductors and flat-screen televisions.

Shionogi seeks approval for Japan’s first domestic COVID pill

National / Science & Health Feb 25, 2022

Shionogi seeks approval for Japan’s first domestic COVID pill

by Osamu Tsukimori

Kishida has signaled that the central government will expedite the review process to pave the way for a swift approval if the drug's efficacy and safety are confirmed.

China’s approval of Pfizer pill opens door to ending 'COVID zero'

Asia Pacific Feb 15, 2022

China’s approval of Pfizer pill opens door to ending 'COVID zero'

Having an effective anti-viral in its arsenal could help China mitigate the lower efficacy of its homegrown vaccines if the virus was allowed to circulate more freely.

Here’s what the pandemic has in store for the world next

World Feb 14, 2022

Here’s what the pandemic has in store for the world next

by Michelle Cortez

As a virus-weary world limps through the third year of the outbreak, experts warn that omicron won't be the last variant we have to contend with.

Japan to consider early approval for Shionogi COVID-19 pill

National Feb 8, 2022

Japan to consider early approval for Shionogi COVID-19 pill

The company could file for early approval of the drug as soon as next week, and it could deliver enough doses for 1 million people by the end of March.

COVID’s endemic shift means a slowdown for virus product makers

World Feb 4, 2022

COVID’s endemic shift means a slowdown for virus product makers

by Marthe Fourcade, Tim Loh and William Wilkes

Demand for at-home tests will probably slow first while sales of more reliable PCRs will show more resilience, according to medical supply executives.

The COVID-19 vaccine we need now may not be a shot

World / Science & Health Feb 3, 2022

The COVID-19 vaccine we need now may not be a shot

by Apoorva Mandavilli

Nasal vaccines may be the best way to prevent infections long term, because they provide protection exactly where it is needed to fend off the virus: the mucosal linings of the airways.

How does Merck's COVID-19 pill compare to Pfizer's?

World / Science & Health Feb 1, 2022

How does Merck's COVID-19 pill compare to Pfizer's?

by Deena Beasley

Pfizer said final trial results showed that its treatment reduced the chance of hospitalization or death by 89%, while Merck said their pill reduced those chances by 30%.

Moderna starts trial for omicron-specific booster shot

World Jan 27, 2022

Moderna starts trial for omicron-specific booster shot

The news comes a day after rival vaccine developer Pfizer Inc. launched a similar trial.

Pfizer and BioNTech launch trial of omicron-targeted COVID-19 vaccine

World Jan 26, 2022

Pfizer and BioNTech launch trial of omicron-targeted COVID-19 vaccine

The companies plan to test the immune response generated by the omicron-based vaccine both as a three-shot regimen in unvaccinated people and as a booster shot.

Pfizer seeks approval for oral COVID-19 pill in Japan

National Jan 14, 2022

Pfizer seeks approval for oral COVID-19 pill in Japan

The country has already agreeing to procure enough of the drug, Paxlovid, for 2 million people

« 1 … 8 9 10 … 42 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times